Verastem, Inc. VSTM
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-15.71
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $30.9M | -$209.5M | — | — | $57.2M |
| 2024 | $10.0M | -$130.6M | — | -$104.8M | -$28.9M |
| 2023 | — | -$87.4M | — | — | $57.4M |
| 2022 | $2.6M | -$73.8M | — | — | $47.4M |
| 2021 | $2.1M | -$71.2M | — | -$53.7M | $87.6M |
| 2020 | $88.5M | -$67.7M | — | -$33.5M | $115.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Paterson Dan | President and CEO | 2026-06-22 | Sell | 20,871 | $4.18 |
| Calkins Daniel | Chief Financial Officer | 2026-06-22 | Sell | 4,032 | $4.18 |
| Calkins Daniel | Chief Financial Officer | 2026-06-22 | Sell | 57 | $4.13 |
| BAILEY MICHAEL P | director | 2026-05-21 | Grant | 108,000 | — |
| Tollefson Karin Anna | director | 2026-05-21 | Grant | 36,000 | — |
| Stuglik Brian M | director | 2026-05-21 | Grant | 36,000 | — |
| Rowinsky Eric K | director | 2026-05-21 | Grant | 36,000 | — |
| ROBERTSON MICHELLE | director | 2026-05-21 | Grant | 36,000 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -15.71 (distress)
- Working capital / assets 0.613
- Retained earnings / assets -4.727
- EBIT / assets -0.69
- Equity / liabilities 0.302
Source: SEC EDGAR filings · CIK 0001526119 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.